The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The projected business potential is around US$ 1 million in the first year
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Globally, BRUKINSA is approved in more than 70 countries
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval is based on positive data from the Phase 3 ECHELON-3 trial
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Subscribe To Our Newsletter & Stay Updated
